Last reviewed · How we verify
NCT04969471: NATURE
NATURE (EnVast as an Adjunct PPCI in Subjects Presenting With STEMI)
NA trial testing enVast stent in Segment Elevation Myocardial Infarction (STEMI) in 148 participants. Participants enrolled and being followed up; not accepting new ones.
1 June 2026
Quick facts
| Lead sponsor | Vesalio |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 148 |
| Start date | 9 December 2021 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 August 2027 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- enVast stent
- conventional treatment — full drug profile →
Conditions studied
- Segment Elevation Myocardial Infarction (STEMI) — all drugs for Segment Elevation Myocardial Infarction (STEMI) →
Sponsor
Vesalio — full company profile →
Who can join
18 and older, any sex, with Segment Elevation Myocardial Infarction (STEMI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to compare the safety and effectiveness of blood clot (thrombus) removal in subjects presenting with ST-segment elevation myocardial infarction (STEMI) with the enVast coronary system versus conventional intervention.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
A prospective, first-in-human use of the NeVa mechanical thrombectomy device for patients with acute coronary syndromes.
Spirito A, Quagliana A, Coiro M, Melaku GD, et al · · 2022 · cited 16× · PMID 34992050 · DOI 10.4244/eij-d-21-00741 -
Machine learning assisted reflectance spectral characterisation of coronary thrombi correlates with microvascular injury in patients with ST-segment elevation acute coronary syndrome.
Kotronias RA, Fielding K, Greenhalgh C, Lee R, et al · · 2022 · cited 5× · PMID 36204570 · DOI 10.3389/fcvm.2022.930015 -
The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial.
Landi A, Biscaglia S, Cuculi F, Erriquez A, et al · · 2026 · PMID 41820070 · DOI 10.1016/j.carrev.2026.03.002
Verify or expand the search:
- PubMed search for NCT04969471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Vesalio trials
Trials by the same sponsor.
- NCT06964724 — NeVa Retrospective Comparative SR Study · active not recruiting
- NCT06893588 — Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts · not yet recruiting
- NCT04562194 — NeVa ONE Registry Study · NA · recruiting
- NCT03611790 — Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04969471 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vesalio
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing